0001209191-20-028801.txt : 20200513
0001209191-20-028801.hdr.sgml : 20200513
20200513162043
ACCESSION NUMBER: 0001209191-20-028801
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200511
FILED AS OF DATE: 20200513
DATE AS OF CHANGE: 20200513
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sachdev Amit
CENTRAL INDEX KEY: 0001406338
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 20873434
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-11
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001406338
Sachdev Amit
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP, Chief Patient Officer
Common Stock
2020-05-11
4
M
0
10665
131.89
A
45768
D
Common Stock
2020-05-11
4
S
0
800
276.25
D
44968
D
Common Stock
2020-05-11
4
S
0
201
277.38
D
44767
D
Common Stock
2020-05-11
4
S
0
655
279.67
D
44112
D
Common Stock
2020-05-11
4
S
0
1817
280.77
D
42295
D
Common Stock
2020-05-11
4
S
0
1398
281.74
D
40897
D
Common Stock
2020-05-11
4
S
0
913
282.89
D
39984
D
Common Stock
2020-05-11
4
S
0
1100
283.98
D
38884
D
Common Stock
2020-05-11
4
S
0
2314
285.15
D
36570
D
Common Stock
2020-05-11
4
S
0
1367
285.94
D
35203
D
Common Stock
2020-05-11
4
S
0
100
286.72
D
35103
D
Common Stock
882
I
401(k)
Common Stock
14002
I
GRAT
Stock Option (Right to Buy)
131.89
2020-05-11
4
M
0
10665
0.00
D
2025-07-20
Common Stock
10665
0
D
Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $276.25 (range $275.73 to $276.52).
Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $277.38 (range $277.26 to $277.50).
Open market sales reported on this line occurred at a weighted average price of $279.67 (range $279.21 to $280.05).
Open market sales reported on this line occurred at a weighted average price of $280.77 (range $280.33 to $281.26).
Open market sales reported on this line occurred at a weighted average price of $281.74 (range $281.33 to $282.29).
Open market sales reported on this line occurred at a weighted average price of $282.89 (range $282.44 to $283.24).
Open market sales reported on this line occurred at a weighted average price of $283.98 (range $283.57 to $284.44).
Open market sales reported on this line occurred at a weighted average price of $285.15 (range $284.57 to $285.55).
Open market sales reported on this line occurred at a weighted average price of $285.94 (range $285.63 to $286.59).
Fully vested.
/s/ Sabrina Yohai, Attorney-in-Fact
2020-05-13